Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
October 31 2023 - 4:01PM
Business Wire
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced it
will release third quarter 2023 financial results after the market
closes on Tuesday, November 7, 2023.
Xencor management will host a webcast and conference call the
same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial
results and provide a corporate update.
The live webcast may be accessed through “Events &
Presentations” in the Investors section of the Company’s website,
located at investors.xencor.com. Telephone participants may
register to receive a dial-in number and unique passcode that can
be used to access the conference call. A recording will be
available for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031645708/en/
Charles Liles cliles@xencor.com 626-737-8118
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Apr 2024 to May 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From May 2023 to May 2024